Progression after the next line of therapy (PFS2) and updated OS among patients with advanced NSCLC and PD-L1 TPS ≥50% enrolled in KEYNOTE-024 - Brahmer, J R (J Clin Oncol, 2017)
(suppl; abstr 9000)